To characterize the soluble peripheral blood protein profiles in NSCLC patients before anti-PD-(L)1 therapy, we performed a multiplex PEA-based analysis of 92 plasma proteins (Table S1). The gene discussed is CD274; the disease is non-small cell lung carcinoma.